Let’s Talk

5-Amino-1MQ (10 mg Vial) Dosage Protocol

Contents

Compound Overview

Chemical Structure & Properties

Origin, Derivation & Development

Mechanism of Action

Potential Benefits & Observed Outcomes

Safety, Side Effects & Risk Considerations

Research Status, Legal & Compliance Context

Handling, Stability & Technical Notes

Certificate of Analysis

References

Recommended Sellers

Compound Overview

5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels[1][2]. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency[3]. This educational protocol presents a subcutaneous injection approach to maximize bioavailability from the 50 mg vial format.

  • Reconstitute: Add 4.0 mL bacteriostatic water → 12.5 mg/mL concentration.
  • Typical daily range: 2.5–5 mg once or twice daily (subcutaneous).
  • Easy measuring: At 12.5 mg/mL, 1 unit = 0.01 mL = 0.125 mg (125 mcg) on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.

Chemical Structure & Properties

Subcutaneous Protocol (4 mL = 12.5 mg/mL)

Phase Daily Dose (mg) Units (per injection) (mL)
Days 1–2 (Tolerance) 2.5 mg once daily 20 units (0.20 mL)
Days 3+ (Standard) 5 mg once daily 40 units (0.40 mL)
Alternative BID 2.5 mg twice daily 20 units (0.20 mL) × 2

Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours[4], twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 50 mg vial provides 10–20 days of research material at these doses.

Reconstitution Steps

  1. Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
  2. Draw 4.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved—solution should be clear (do not shake).
  5. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Origin, Derivation & Development

Supplies Needed

Plan based on research duration using the 50 mg vial format at 5 mg/day.

  • 5-Amino-1MQ Vials (50 mg each):
    • 1 week (5 mg/day) ≈ 1 vial
    • 2 weeks (5 mg/day) ≈ 1 vial
    • 4 weeks (5 mg/day) ≈ 2 vials
  • Insulin Syringes (U-100):
    • Per week (once daily): 7 syringes
    • Per week (BID): 14 syringes
    • 4 weeks (once daily): 28 syringes
  • Bacteriostatic Water (10 mL bottles): Use 4.0 mL per vial for reconstitution.
    • 1 week (1 vial): 4 mL → 1 × 10 mL bottle
    • 2 weeks (1 vial): 4 mL → 1 × 10 mL bottle
    • 4 weeks (2 vials): 8 mL → 1 × 10 mL bottle
  • Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
    • Per week (once daily): 14 swabs
    • 4 weeks (once daily): 56 swabs → recommend 1 × 100-count box

Mechanism of Action

Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels[1][2].
  • Schedule: Daily subcutaneous injections; each 50 mg vial provides 10–20 days of research material.
  • Dose Range: 2.5–5 mg once or twice daily.
  • Reconstitution: 4.0 mL per 50 mg vial (12.5 mg/mL) for accurate measurements.
  • Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).

 Dosing Protocol

Suggested approach for the 50 mg vial format.

  • Start: 2.5 mg once daily to assess tolerance.
  • Target: 5 mg once daily or 2.5 mg twice daily (BID).
  • Frequency: Once or twice per day (subcutaneous).
  • Vial Duration: Single 50 mg vial lasts 10–20 days at research doses.
  • Timing: Morning administration preferred; BID dosing may be split AM/PM.

 Storage Instructions

Proper storage preserves compound stability.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
  • Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
  • Do not refreeze reconstituted solution.

Potential Benefits & Observed Outcomes

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes for each administration; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
  • Document daily dose and site rotation to maintain consistency.
  • The 50 mg vial format is ideal for extended research cycles; a single vial can last 10–20 days.

Safety, Side Effects & Risk Considerations

How This Works

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT)[1]. NNMT is an enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability[2].

By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis and fat oxidation[3]. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake[5][6].

Research Status, Legal & Compliance Context

Potential Benefits & Side Effects

Observations from preclinical and early research literature.

  • May support reductions in fat mass while preserving lean muscle in animal models[5][6].
  • Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies[2][3].
  • Enhanced grip strength observed in aged mice when combined with exercise[7].
  • Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions.
  • Long-term human safety data not established; this compound remains investigational.

Handling, Stability & Technical Notes

Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, protein-forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity—preclinical data suggest synergy with exercise[7].
  • Prioritize sleep and stress management to support metabolic adaptation.
  • Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols[8].

Certificate of Analysis

Injection Technique

General subcutaneous guidance from clinical best-practice resources[9].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[10][11].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[12].
  • Slow injection may minimize any stinging sensation associated with the compound.

References

No data was found
Scroll to Top
Facebook X-twitter Youtube

Have Project?

[email protected]

Want to Work With Me

Send Brief

Want to Buy Books?

Go to Shop
+1 800 355 55 65
[email protected]